SLC22A1 and neoplasm: The under-expression of SLC22A1, SLC22A2, SLC47A1, CTR1, and CTR2 leads to reduce uptake of cisplatin whereas the upregulation of ATP7A, ATP7B, MRP1, MRP2, and MRP4 are responsible for increased efflux of cisplatin out of the tumor cell.